PressJanuary 30, 2024 FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates
PressJanuary 30, 2024 Huxley Health Inc. Provides Corporate Update – Appoints Bruce Linton as Chairman
PressJanuary 30, 2024 MindBio Therapeutics Corp. Announces Completion of Landmark Phase 2A LSD Microdosing Clinical Trial in Distressive Disorder
PressJanuary 29, 2024 Nirvana Life Sciences Inc. Announces Receipt of First North American Production of SOSA, a Patented, WHO Approved, Herbal Treatment for Opiate Addiction
PressJanuary 26, 2024 Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
PressJanuary 26, 2024 PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada.
PressJanuary 25, 2024 Red Light Holland Announces Strategic Changes and Launch of SR Wholesale North America, a Fresh Mushroom Sales Division
PressJanuary 24, 2024 Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
PressJanuary 24, 2024 Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers
PressJanuary 23, 2024 Red Light Holland’s Homogenized Psilocybin Microdosing Capsules Complete Product Specification Document by cGMP Pharmaceutical Company CCrest Laboratories, Provided to NUBU Pharmaceuticals in Australasia
PressJanuary 23, 2024 Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
PressJanuary 23, 2024 Newcourt Acquisition Corp Announces Continuation of Business Combination Close Process
PressJanuary 19, 2024 Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
PressJanuary 18, 2024 Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences
PressJanuary 18, 2024 Clearmind Medicine Inc. Selects Aegis Capital Corp. as Sole Bookrunner for $2.4M Private Placement
PressJanuary 17, 2024 Filament Health Completes the First Export of Botanical Psilocybin to Australia
PressJanuary 17, 2024 Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
PressJanuary 17, 2024 MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement
PressJanuary 16, 2024 Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination
